Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.annder.2023.103243 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Role of Radiotherapy in the Management of Melanoma Brain Metastases: An Overview.
Curr Treat Options Oncol
January 2025
Ella Lemelbaum Institute for Immuno Oncology, Chaim Sheba Medical Center, 6997801, Tel Aviv, Israel.
Clinical management of melanoma brain metastases is complex and requires multidisciplinary approach. With close collaboration between neurosurgeons, radiation oncologists and medical oncologists, melanoma patients with brain are offered different treatment modalities: surgery, radiation therapy, systemic therapy or combined treatments. Radiation therapy (whole brain radiotherapy- WBRT and stereotactic radiosurgery- SRS) is an integral part of treating melanoma brain metastases.
View Article and Find Full Text PDFFractionated low-dose radiotherapy primes the tumor microenvironment for immunotherapy in a murine mesothelioma model.
Cancer Immunol Immunother
January 2025
National Centre for Asbestos Related Diseases, The University of Western Australia, Perth, Australia.
Combination immune checkpoint inhibitors (nivolumab and ipilimumab) are currently a first-line treatment for mesothelioma; however, not all patients respond. The efficacy of treatment is influenced by the tumor microenvironment. Murine mesothelioma tumors were irritated with various radiotherapy doses.
View Article and Find Full Text PDFEfficacy and safety of nivolumab and ipilimumab with or without chemotherapy for unresectable non-small cell lung cancer: a multicenter retrospective observational study.
Cancer Immunol Immunother
January 2025
Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Introduction: Compared to platinum-based therapies, a combination of ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) has demonstrated improved outcomes in advanced non-small cell lung cancer (NSCLC), albeit with higher rates of immune-related adverse events (irAEs). This multicenter retrospective study evaluated the efficacy and safety of nivolumab and ipilimumab with or without chemotherapy (NI and NICT) in real-world clinical settings.
Methods: We enrolled 215 treatment-naïve NSCLC patients who received NI or NICT between December 2020 and May 2023 at 14 institutions in Japan.
Cytokine release syndrome treated with tocilizumab following ipilimumab-nivolumab combination therapy in advanced renal cell carcinoma.
IJU Case Rep
January 2025
Department of Urology, Faculty of Medicine Oita University Yufu Oita Japan.
Introduction: Cytokine release syndrome is a rare but potentially life-threatening complication of immune checkpoint inhibitor therapy. Its occurrence in renal cell carcinoma treated with combination therapy is less recognized and poses significant management challenges.
Case Presentation: A 50-year-old male with metastatic renal cell carcinoma developed severe cytokine release syndrome after receiving ipilimumab-nivolumab combination therapy.
Background And Objective: Patients receiving immune checkpoint blockade (ICB) therapy may experience periods of prolonged disease control without a need for systemic therapy. Treatment-free survival (TFS) is an important measure for this period, but no data are available for patients with metastatic renal cell carcinoma (mRCC) starting first-line agents. Our aim was to analyze TFS outcomes for patients with mRCC starting first-line therapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!